The Cure Is Real. The Bottleneck Isn’t Scientific. So Why Is San Rocco Missing From the Story?

Two years after the U.S. Food and Drug Administration (FDA) first approvals of gene therapies for sickle cell disease, the central question is no longer whether cures are possible. It is who actually gets cured—and at what cost. That paradox sits at the center of a recent Politico investigation: spectacular science constrained by multimillion-dollar price tags, scarce treatment infrastructure, and payer bureaucracy so burdensome that many patients—especially Medicaid patients and those outside major metros—remain stuck in line.

Yet one name remains largely absent from the mainstream conversation: San Rocco Therapeutics, a developer that TrialSite has chronicled for years as a would-be “access-first” entrant in sickle cell and thalassemia gene therapy. Although now entering later stage clinical trials, the omission matters, because if the policy debate is truly about affordability and scalability, then ignoring a company explicitly positioning itself as lower-cost is not a neutral editorial choice—it shapes what solutions the public is even allowed to imagine.

View the rest of the article here

View the PDF